J. Kantrowitz

发表

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?

D. Javitt, J. Kantrowitz, Joshua T. Kantrowitz, 2010, Brain Research Bulletin.

Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia

D. Javitt, P. Sehatpour, M. Hoptman, 2015, The Journal of Neuroscience.

Neural mechanisms of mismatch negativity (MMN) dysfunction in schizophrenia

Pejman Sehatpour, Daniel C. Javitt, Matthew J. Hoptman, 2016, Molecular Psychiatry.

Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.

M. Ahissar, D. Javitt, M. Epstein, 2016, Brain : a journal of neurology.

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms

J. Lieberman, D. Javitt, J. Ragland, 2019, NeuroImage: Clinical.

The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder

D. Javitt, M. Hoptman, D. Leitman, 2013, Psychological Medicine.

Handbook of neurochemistry and molecular neurobiology, schizophrenia

A. Lajtha, D. Javitt, J. Kantrowitz, 2009 .

Evidencein Human Auditory Cortex: MEG Concurrent Encoding of Frequency and Amplitude

D. Poeppel, J. Obleser, D. Javitt, 2015 .

Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers

Michael F. Green, J. Lieberman, D. Javitt, 2020 .

Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

J. Kantrowitz, Joshua T. Kantrowitz, 2017, CNS Drugs.

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

J. Lieberman, D. Javitt, J. Ragland, 2018, JAMA psychiatry.

Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study

D. Javitt, L. Kegeles, A. Abi-Dargham, 2019, Psychiatry Research.

A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia

D. Javitt, Antígona Martínez, P. Sehatpour, 2018, Schizophrenia Research.

Illness Phase as a Key Assessment and Intervention Window for Psychosis

Jared X. Van Snellenberg, J. Lieberman, J. Grinband, 2022, Biological psychiatry global open science.

A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia.

D. Javitt, L. Citrome, J. Kantrowitz, 2009, Clinical therapeutics.

Resolution of Transient Ischemic Attacks and Aortic Arch Thrombi on Anticoagulant Therapy

R. Holloway, J. Kantrowitz, D. Giang, 2000, European Neurology.

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms

D. Javitt, E. Petkova, M. Epstein, 2018, Schizophrenia Research.

Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients

J. Lieberman, D. Javitt, J. Grinband, 2020, Neuropsychopharmacology.

Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia

D. Javitt, Antígona Martínez, G. Patel, 2019, Translational Psychiatry.

Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058

D. Javitt, P. Sehatpour, D. Margolin, 2021, Neuropsychopharmacology.

Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia †

J. Lieberman, P. Sehatpour, L. Kegeles, 2020, Journal of psychiatry and brain science.

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.

D. Javitt, S. Woods, E. Petkova, 2015, The lancet. Psychiatry.

Sleep disturbances in individuals at clinical high risk for psychosis

R. Girgis, T. Colibazzi, C. Corcoran, 2017, Psychiatry Research.

Amusia and protolanguage impairments in schizophrenia

Hillary Anger Elfenbein, D. Javitt, P. Laukka, 2014, Psychological Medicine.

Neural and functional correlates of impaired reading ability in schizophrenia

D. Javitt, Antígona Martínez, P. Sehatpour, 2019, Scientific Reports.

Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

D. Javitt, J. Brunelin, A. Brunoni, 2022, Schizophrenia bulletin.

GABAB Receptors, Schizophrenia and Sleep Dysfunction

D. Javitt, L. Citrome, J. Kantrowitz, 2009, CNS drugs.

Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting

J. Kantrowitz, Marlene Carlson, Joshua T. Kantrowitz, 2022, The international journal of neuropsychopharmacology.

Schizoaffective Disorder

L. Citrome, J. Kantrowitz, 2011, CNS drugs.

Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches

J. Kantrowitz, Joshua T. Kantrowitz, 2020, CNS Drugs.

D-Serine: A Cross Species Review of Safety

J. Kantrowitz, H. Hasegawa, Joshua T. Kantrowitz, 2021, Frontiers in Psychiatry.

Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study

J. Lieberman, J. Kantrowitz, C. Clelland, 2020, Schizophrenia Research.

Seeing the world dimly: the impact of early visual deficits on visual experience in schizophrenia.

Gail Silipo, Daniel C Javitt, D. Javitt, 2009, Schizophrenia bulletin.

The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions

Kristen M. Haut, Rachael K. Blackman, L. DeLisi, 2012, Schizophrenia Research.

Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers

Michael F. Green, J. Lieberman, D. Javitt, 2020, Neuropsychopharmacology.

High dose D-serine in the treatment of schizophrenia

Daniel C. Javitt, Anil K. Malhotra, Scott W. Woods, 2010, Schizophrenia Research.

Glutamatergic transmission in schizophrenia: from basic research to clinical practice

Daniel C Javitt, D. Javitt, J. Kantrowitz, 2012, Current opinion in psychiatry.

Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

D. Javitt, J. Kantrowitz, Joshua T. Kantrowitz, 2010, Clinical schizophrenia & related psychoses.

Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention

S A Small, F Provenzano, J. Lieberman, 2018, Molecular Psychiatry.

Olanzapine: review of safety 2008

L. Citrome, J. Kantrowitz, Joshua T. Kantrowitz, 2008 .

Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?

L. Citrome, J. Kantrowitz, Joshua T. Kantrowitz, 2009, Expert review of neurotherapeutics.

Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study

M. Milak, Z. Dong, M. Lan, 2021, Frontiers in Psychiatry.

Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia

D. Javitt, G. Silipo, J. Kantrowitz, 2018, Schizophrenia Research.

Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.

N. Swerdlow, S. Vinogradov, J. Kantrowitz, 2018, Biological psychiatry. Cognitive neuroscience and neuroimaging.

GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.

D. Javitt, L. Citrome, J. Kantrowitz, 2009, CNS drugs.

Paliperidone: the evidence of its therapeutic value in schizophrenia

L. Citrome, J. Kantrowitz, Joshua T. Kantrowitz, 2007, Core evidence.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia

Alan S. Brown, J. Lieberman, S. Cremers, 2017, Neuropsychopharmacology.

Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings

Daniel C. Javitt, Jeffrey A. Lieberman, Anissa Abi-Dargham, 2014, Schizophrenia Research.

N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia

J. Kantrowitz, 2018, Schizophrenia Research.

Risk of psychosis exacerbation by tricyclic antidepressants in unipolar Major Depressive Disorder with psychotic features.

J. Kantrowitz, Joshua T. Kantrowitz, R. Tampi, 2008, Journal of affective disorders.

Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.

Jared X. Van Snellenberg, J. Grinband, R. Gur, 2021, Schizophrenia bulletin.

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

M Slifstein, J. Lieberman, D. Javitt, 2014, Molecular Psychiatry.

Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder

J. Lieberman, D. Javitt, L. Kegeles, 2021, Translational Psychiatry.

Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.

J. Kantrowitz, J. Gangwisch, Joshua T. Kantrowitz, 2015, The Journal of clinical psychiatry.

Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians

S. Sen, K. Nolan, H. Lachman, 2009, Psychiatric Quarterly.

Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia

D. Javitt, Antígona Martínez, J. Kantrowitz, 2018, Schizophrenia Research.

Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine

P. Sehatpour, L. Kegeles, R. Girgis, 2023, Biological Psychiatry.

Early auditory processing dysfunction in schizophrenia: Mechanisms and implications

D. Javitt, Antígona Martínez, P. Sehatpour, 2023, Neuroscience & Biobehavioral Reviews.

Auditory tasks for assessment of sensory function and affective prosody in schizophrenia.

D. Javitt, E. Petkova, P. Butler, 2014, Comprehensive psychiatry.

Neurophysiological Effects of Bitopertin in Schizophrenia

D. Javitt, E. Petkova, K. Nolan, 2017, Journal of clinical psychopharmacology.

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks

Leslie Citrome, L. Citrome, J. Kantrowitz, 2008, Expert review of neurotherapeutics.

New discoveries for an old drug: a review of recent olanzapine research

L. Citrome, J. Kantrowitz, Joshua T. Kantrowitz, 2019, Postgraduate medicine.

New Developments in the Treatment of Schizophrenia: An Expert Roundtable

C. Correll, J. Kantrowitz, A. Cutler, 2023, The international journal of neuropsychopharmacology.

Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition.

D. Javitt, R. Gur, John A. Hansen, 2012, The American journal of psychiatry.

Reduction in tonal discriminations predicts receptive emotion processing deficits in schizophrenia and schizoaffective disorder.

D. Javitt, P. Laukka, P. Juslin, 2013, Schizophrenia bulletin.

Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions

J. Kantrowitz, Joshua T. Kantrowitz, 2021, CNS Drugs.

Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study

D. Javitt, P. Sehatpour, R. Girgis, 2019, Brain Stimulation.

Additional perspective on cariprazine and negative symptoms

J. Kantrowitz, 2021, Expert opinion on pharmacotherapy.

How do we address treating the negative symptoms of schizophrenia pharmacologically?

J. Kantrowitz, 2021, Expert opinion on pharmacotherapy.

The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease

D. Javitt, J. Kantrowitz, Joshua T. Kantrowitz, 2022, Schizophrenia Research.

Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study

P. Sehatpour, J. Kantrowitz, T. Sobeih, 2023, Research square.

Carbamazepine and oxcarbazepine for the treatment of behavioural and psychological symptoms of dementia (BPSD)

J. Kantrowitz, Kirsten M. Wilkins, R. Tampi, 2009, Cochrane Database of Systematic Reviews.

d-Cycloserine, an NMDA Glutamate Receptor Glycine Site Partial Agonist, Induces Acute Increases in Brain Glutamate Plus Glutamine and GABA Comparable to Ketamine.

J. Mann, M. Milak, X. Mao, 2016, The American journal of psychiatry.

Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia

D. Javitt, Antígona Martínez, P. Sehatpour, 2021, Frontiers in Psychiatry.

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

Michael F. Green, J. Lieberman, C. Carter, 2015, Schizophrenia Research.

It's all in the cards: effect of stimulus manipulation on Wisconsin Card Sorting Test performance in schizophrenia

D. Javitt, G. Silipo, J. Kantrowitz, 2009, Psychiatry Research.

Neurons: Impact of Chloride Extrusion Capacity Differential Maturation of GABA Action and Anion Reversal Potential in Spinal Lamina I

Y. Koninck, Jian Kang, Li Jiang, 2015 .

The Potential Role of Lumateperone-Something Borrowed? Something New?

J. Kantrowitz, 2020, JAMA psychiatry.

Synaptic depolarizing GABA Response in adults is excitatory and proconvulsive when GABAB receptors are blocked.

J. Kantrowitz, K. L. Perkins, A. Salah, 2005, Journal of neurophysiology.

Receptors Are Blocked B Excitatory and Proconvulsive When GABA Synaptic Depolarizing GABA Response in Adults Is

T. Fukai, M. Takada, M. Kokaia, 2015 .

Three cases of risperidone-induced enuresis

C. Tek, V. Srihari, J. Kantrowitz, 2006, Schizophrenia Research.

Lurasidone for schizophrenia: what’s different?

L. Citrome, J. Kantrowitz, 2012, Expert review of neurotherapeutics.

A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder.

Philip D. Harvey, J. Lieberman, D. Barch, 2016, The Journal of clinical psychiatry.